CAMAC’s March 2014 managed investment schemes paper — a precursor to the FSI?
By Andrew Yik
The Corporations and Markets Advisory Committee (CAMAC) has released a broad discussion paper to review the establishment and management of schemes, which opens up all aspects of the legislative structure. Its objective is to reduce compliance burdens, and for the regulatory regime for schemes to be aligned with that for companies, unless there are compelling reasons to treat schemes differently.
This is a continuation of the review that produced the CAMAC July 2012 Report, and may provide a useful indication of the issues that the Financial System Inquiry (FSI) will consider in relation to managed investment schemes.
This paper will be of interest to the operators and investors in managed investment schemes…
Click on the link below to read the rest of the Minter Ellison briefing.
Sign in or Register to continue reading this article
It's quick, easy and free!
It takes just 5 minutes to register. Answer a few simple questions and once completed you’ll have instant access.Register now
Why register to The Lawyer
In-depth, expert analysis into the stories behind the headlines from our leading team of journalists.
Identify the major players and business opportunities within a particular region through our series of free, special reports.
Receive your pick of The Lawyer's daily and weekly email newsletters, tailored by practice area, region and job function.
More relevant to you
To continue providing the best analysis, insight and news across the legal market we are collecting some information about who you are, what you do and where you work to improve The Lawyer and make it more relevant to you.
News from Minter Ellison
News from The Lawyer
Briefings from Minter Ellison
Asia Region Funds Passport: draft rules a step towards a regional market for managed investment funds
The Asia Region Funds Passport will create a regional market for managed investment funds and give Australian fund managers an opportunity to increase their presence in Asia.
The Federal Court of Australia has dismissed the ACCC’s anti-competitive conduct case against Pfizer, finding that Pfizer did not breach the prohibition on misuse of market power.